DUBLIN--(BUSINESS WIRE)--May 14, 2018--The "Drug Overview: QVM149" report has been added to ResearchAndMarkets.com's offering.

QVM149 (Novartis) is a fixed triple combination product consisting of a long-acting muscarinic antagonist (glycopyrronium bromide), a long-acting beta 2 agonist (LABA) (indacaterol), and an inhaled corticosteroid (ICS) (mometasone furoate). QVM149 is in Phase III development for the treatment of moderate to severe asthma uncontrolled with standard ICS/LABA therapies.

Key Topics Covered:

Product Profiles

QVM149: Asthma

List of Figures

Figure 1: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 2: Symbicort for asthma - SWOT analysis

List of Tables

Table 1: QVM149 drug profile

Table 2: QVM149 Phase III trials in asthma

Table 3: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/kj52wl/qvm149_novartis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514006238/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Asthma Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 02:52 PM/DISC: 05/14/2018 02:52 PM

http://www.businesswire.com/news/home/20180514006238/en